Newsletter | August 1, 2024

08.01.24 -- Sandoz Launches Biosimilar Pyzchiva Across Europe

SPONSOR

PDA/FDA Joint Regulatory Conference 2024

The PDA/FDA Joint Regulatory Conference 2024, the only FDA co-sponsored pharmaceutical CGMP conference, is taking place 9 to 11 September in Washington, D.C. Now in its 33rd year, the conference will offer a comprehensive agenda with substantive technical sessions and practical case studies that provide insight into the effective application of Current Good Manufacturing Practice (CGMP).

FEATURED EDITORIAL

Bacterial Endotoxin Testing, Part 1: Overview

All injectable drug products and implantable medical devices that come into contact with the bloodstream or spinal fluid are tested for endotoxins. This article provides an overview of bacterial endotoxin testing and the LAL method.

5 Recommendations To Maximize CSV/CSA Outcomes

The computer system validation (CSV)/computer system assurance (CSA) process is correlated with other departments besides IT and quality. Accordingly, all stakeholders must think ahead and define what they need.

INDUSTRY INSIGHTS

Derisking Biomanufacturing: How A CDMO In Poland Could Help You

The current geopolitical climate is leading drug developers to consider global manufacturing partnerships strategically. Identify a CDMO partner that will help protect your IP, save money, and mitigate risk.

Characterizing The E&L Profile Of Stoppers For Drug Stability

The significance of E&L testing lies in its ability to identify potential risks associated with the use of containers and packaging materials in the pharmaceutical industry.

Strategies For Ensuring Virus Bank Manufacturing Success

Learn about the processes and best practices applied at a GMP facility to optimize the production of working virus seed stocks and master virus seed stocks.

NEWS HEADLINES

Sandoz Launches Biosimilar Pyzchiva (ustekinumab) Across Europe, To Treat Chronic Inflammatory Diseases

Kashiv BioSciences Announces Completion Of Enrollment For Phase III Clinical Trial Of ADL018, A Biosimilar Candidate To XOLAIR (Omalizumab)

Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial For BAT3306, A Proposed Biosimilar Of Keytruda (Pembrolizumab)

FDA Approves Samsung Bioepis' EPYSQLI (eculizumab-aagh) As A Biosimilar To Soliris (eculizumab)

SOLUTIONS

A Semi-Automated Tangential Flow Filtration System